Anaplastic Thyroid Carcinoma

Management continued - targets

• 70% PD-L1 ≥70%
• 73% TPS ≥5%
• 10-15% dMMR
• 20-45% BRAF (dabrafenib-trametinib¹, vemurafenib, cobimetinib)
• 2-3% ALK (crizotinib, brigatinib, ceritinib)
• 2-3% NTRK (larotrectinib, entrectinib)
• 2-3% RET (selpercatinib, praseltinib)
• mKI - lenvatinib